Yahoo
NasdaqGS - Nasdaq Real Time Price USD

MacroGenics, Inc. (MGNX)

2.3800 -0.0900 (-3.64%)
At close: October 29 at 4:00:00 PM EDT
2.4073 +0.0273 (+1.15%)
After hours: October 29 at 7:41:43 PM EDT
Trade MGNX on Coinbase
Chart Range Bar
Loading chart for MGNX
Chart does not reflect overnight price.
  • Previous Close 2.4700
  • Open 2.4900
  • Bid 1.8700 x 200
  • Ask 3.0700 x 200
  • Day's Range 2.3700 - 2.5900
  • 52 Week Range 1.2900 - 5.0800
  • Volume 741,412
  • Avg. Volume 661,281
  • Market Cap (intraday) 151.606M
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) --
  • EPS (TTM) -1.7000
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 8.00
  • Zacks Rating Neutral

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

www.macrogenics.com

293

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MGNX
47.83%
S&P 500 (^GSPC)
12.78%

1-Year Return

MGNX
40.83%
S&P 500 (^GSPC)
12.04%

3-Year Return

MGNX
52.02%
S&P 500 (^GSPC)
87.51%

5-Year Return

MGNX
87.81%
S&P 500 (^GSPC)
67.64%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 32.83M
Earnings 19.52M
Profit Margin 59.44%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
0
20M
40M
60M
-150.0%
-100.0%
-50.0%
0.0%
50.0%

Analyst Insights

View More

Analyst Price Targets

4.00
8.00 Average
2.3800 Current
11.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/17/2026
Analyst B. Riley Securities
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 9 -> 11

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    157.98M

  • Enterprise Value

    19.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    1.02

  • Price/Book (mrq)

    3.68

  • Enterprise Value/Revenue

    0.13

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.33%

  • Return on Assets (ttm)

    -8.05%

  • Return on Equity (ttm)

    -225.85%

  • Revenue (ttm)

    175.14M

  • Net Income Avi to Common (ttm)

    -101.06M

  • Diluted EPS (ttm)

    -1.7000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    173.3M

  • Total Debt/Equity (mrq)

    81.85%

  • Levered Free Cash Flow (ttm)

    -69.41M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.3800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 10/05/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 09/12/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 09/05/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 02/17/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: